<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Collaboration</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Genomics and Greywolf partner in autoimmune diseases</title>
      <description>
        <![CDATA[Genomics Ltd. has established a strategic relationship with Grey Wolf Therapeutics Ltd. (Greywolf) to develop first-in-class treatments for autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730795</guid>
      <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730795-genomics-and-greywolf-partner-in-autoimmune-diseases</link>
    </item>
    <item>
      <title>Astrazeneca exercises option for Pinetree’s PTX-299</title>
      <description>
        <![CDATA[Astrazeneca plc has exercised an option under its collaboration with Pinetree Therapeutics Inc. to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR. The option exercise triggers a $25 million payment to Pinetree.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730793</guid>
      <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730793-astrazeneca-exercises-option-for-pinetrees-ptx-299</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/dollar-idea-lightbulb.webp?t=1588794062" type="image/png" medium="image" fileSize="331510">
        <media:title type="plain">Dollar sign in lightbulb</media:title>
      </media:content>
    </item>
    <item>
      <title>Milestone in Atrium and BMS cardiovascular collaboration</title>
      <description>
        <![CDATA[Atrium Therapeutics Inc. has earned a $15 million development milestone payment from Bristol Myers Squibb Co. (BMS) for the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the companies’ ongoing collaboration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730635</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730635-milestone-in-atrium-and-bms-cardiovascular-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Vacsular-system.webp?t=1639599093" type="image/png" medium="image" fileSize="555720">
        <media:title type="plain">Vascular system</media:title>
      </media:content>
    </item>
    <item>
      <title>Entos and L-CMD Research Foundation collaborate</title>
      <description>
        <![CDATA[Entos Pharmaceuticals Inc. has established a collaboration with the L-CMD Research Foundation with the aim of developing a curative therapy for LMNA-related congenital muscular dystrophy (L-CMD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730541</guid>
      <pubDate>Tue, 21 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730541-entos-and-l-cmd-research-foundation-collaborate</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Collaboration-illustration.webp?t=1600375790" type="image/png" medium="image" fileSize="669559">
        <media:title type="plain">Deal illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Biogen to use Alloy Therapeutics’ Anticlastic ASO platform</title>
      <description>
        <![CDATA[Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. for the use of Alloy’s Anticlastic ASO platform to accelerate the development of innovative oligonucleotide therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730189</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730189-biogen-to-use-alloy-therapeutics-anticlastic-aso-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Researcher-antisense-oligonucleotides.webp?t=1775662140" type="image/jpeg" medium="image" fileSize="579461">
        <media:title type="plain">AI generated image for researcher developing antisense oligonucleotides</media:title>
      </media:content>
    </item>
    <item>
      <title>Akari Therapeutics partners with Wuxi XDC on ADC payload</title>
      <description>
        <![CDATA[Akari Therapeutics plc has established a strategic partnership with Wuxi XDC Cayman Inc. to accelerate the development of Akari’s novel PH1 payload. Akari’s lead program, AKTX-101, is initially targeting metastatic urothelial cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730165</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730165-akari-therapeutics-partners-with-wuxi-xdc-on-adc-payload</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibody-drug-conjugate-cytotoxic-payload.webp?t=1690210650" type="image/jpeg" medium="image" fileSize="142424">
        <media:title type="plain">3D rendering of antibody drug conjugated with cytotoxic payload</media:title>
      </media:content>
    </item>
    <item>
      <title>Insilico Medicine and Aska enter gynecological collaboration</title>
      <description>
        <![CDATA[Insilico Medicine Cayman Topco has established a strategic research collaboration with Aska Pharmaceutical Co. Ltd. to identify novel therapeutic targets for challenging gynecological conditions, including endometriosis, uterine fibroids and adenomyosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729879</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729879-insilico-medicine-and-aska-enter-gynecological-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Gynecology-womens-health-female-reproductive-system.webp?t=1774455533" type="image/jpeg" medium="image" fileSize="650388">
        <media:title type="plain">Futuristic medical hologram illustration featuring the female reproductive system</media:title>
      </media:content>
    </item>
    <item>
      <title>Insitro and Bristol Myers Squibb expand ALS collaboration</title>
      <description>
        <![CDATA[Insitro Inc. has expanded its strategic collaboration with Bristol Myers Squibb Co. to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS).&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/729858</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729858-insitro-and-bristol-myers-squibb-expand-als-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Demyelination-of-a-neuron.webp?t=1687357719" type="image/jpeg" medium="image" fileSize="237601">
        <media:title type="plain">Demyelination of a neuron</media:title>
      </media:content>
    </item>
    <item>
      <title>Glyconex and Nippon Kayaku collaborate on GNX201-ADC</title>
      <description>
        <![CDATA[Glyconex Inc. has entered into a collaboration agreement with Nippon Kayaku Co. Ltd. to advance GNX201-ADC, a next-generation glycan-directed antibody-drug conjugate (ADC) candidate for the treatment of solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729857</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729857-glyconex-and-nippon-kayaku-collaborate-on-gnx201-adc</link>
    </item>
    <item>
      <title>New Danish research program targets α-synuclein in Parkinson’s</title>
      <description>
        <![CDATA[A new Danish research project focused on Parkinson’s disease has received funding from Innovation Fund Denmark. The DESYNA (Degradation of Extracellular α-SYNuclein Aggregates) project aims to develop a new therapy targeting α-synuclein, the accumulation of which is a key driver of Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729792</guid>
      <pubDate>Mon, 23 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729792-new-danish-research-program-targets-synuclein-in-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Alpha-synuclein.webp?t=1719584612" type="image/jpeg" medium="image" fileSize="77677">
        <media:title type="plain">3D structure model of α-synuclein</media:title>
      </media:content>
    </item>
    <item>
      <title>Alloy Therapeutics and Abbvie partner on antibody platform</title>
      <description>
        <![CDATA[Alloy Therapeutics Inc. has entered into an agreement with Abbvie Inc. to develop a new antibody platform to discover antibodies against targets that are difficult to address with current technologies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729674</guid>
      <pubDate>Tue, 17 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729674-alloy-therapeutics-and-abbvie-partner-on-antibody-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/antibodies-lab-research.webp?t=1717686528" type="image/jpeg" medium="image" fileSize="266442">
        <media:title type="plain">Lab glassware and antibodies art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Aptar and Covirix Medical collaborate on inhaled antivirals</title>
      <description>
        <![CDATA[Aptar Pharma, part of Aptargroup Inc., has established a technical collaboration with Covirix Medical Pty Ltd. under a letter of intent to develop inhaled antiviral treatments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729629</guid>
      <pubDate>Fri, 13 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729629-aptar-and-covirix-medical-collaborate-on-inhaled-antivirals</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Virus-and-drug-illustration.webp?t=1637179016" type="image/png" medium="image" fileSize="294622">
        <media:title type="plain">Virus and drug illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Newcelx partners with Eledon to advance NCEL-101</title>
      <description>
        <![CDATA[Newcelx Ltd. has entered into a collaborative research agreement with Eledon Pharmaceuticals Inc. with the aim of advancing its lead program, NCEL-101, for type 1 diabetes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729416</guid>
      <pubDate>Mon, 09 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729416-newcelx-partners-with-eledon-to-advance-ncel-101</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Insulin-glucose-endocrine-metabolim.webp?t=1673451854" type="image/png" medium="image" fileSize="678616">
        <media:title type="plain">Diagram of how cells take up glucose from the stomach and insulin from the pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Zelluna, Etcembly partner on AI-enabled T-cell receptor engineering</title>
      <description>
        <![CDATA[Zelluna ASA has established a collaboration with Etcembly Ltd. that will focus on the engineering of high-affinity, tumor-specific T-cell receptors targeting KKLC1.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729415</guid>
      <pubDate>Mon, 09 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729415-zelluna-etcembly-partner-on-ai-enabled-t-cell-receptor-engineering</link>
    </item>
    <item>
      <title>Sinopia and Ono collaborate in metabolic disorders</title>
      <description>
        <![CDATA[Sinopia Biosciences Inc. has entered into a target discovery collaboration with Ono Pharmaceutical Co. Ltd. focused on a group of rare metabolic disorders with significant unmet medical need.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729328</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729328-sinopia-and-ono-collaborate-in-metabolic-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Diabetes/human-body-metabolism.webp?t=1726239536" type="image/jpeg" medium="image" fileSize="320060">
        <media:title type="plain">Art concept for metabolism</media:title>
      </media:content>
    </item>
    <item>
      <title>Antiverse announces series A financing, tie-up with CF Foundation</title>
      <description>
        <![CDATA[Antiverse Ltd. has announced the close of a $9.3 million series A financing. The funding will support expansion of the company’s proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729324</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729324-antiverse-announces-series-a-financing-tie-up-with-cf-foundation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibodies-research-discovery-immune.webp?t=1772641847" type="image/jpeg" medium="image" fileSize="240482">
        <media:title type="plain">Illustration of magnifying glass and antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Ono and Congruence expand drug discovery collaboration</title>
      <description>
        <![CDATA[Ono Pharmaceutical Co. Ltd. has entered into an agreement to expand its drug discovery collaboration agreement with Congruence Therapeutics Inc. for the discovery of novel small-molecule modulators against multiple protein targets in the areas of neurology and immunology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729155</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729155-ono-and-congruence-expand-drug-discovery-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/business-strategy-development.webp?t=1588793925" type="image/png" medium="image" fileSize="1357286">
        <media:title type="plain">Blocks with gears, lightbulb, target, magnifying glass </media:title>
      </media:content>
    </item>
    <item>
      <title>Cure Rare Disease signs ANO5-related disease partnership</title>
      <description>
        <![CDATA[Cure Rare Disease has entered into a multiyear partnership with the LGMD2L Foundation to develop a gene replacement therapy for anoctamin 5 (ANO5)-related disease, a rare genetic disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729153</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729153-cure-rare-disease-signs-ano5-related-disease-partnership</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/DNA-dollars.webp?t=1588782408" type="image/png" medium="image" fileSize="377807">
        <media:title type="plain">DNA, dollars illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Angelini and Quiver Bioscience partner in genetic epilepsies</title>
      <description>
        <![CDATA[Angelini Pharma SpA and Quiver Bioscience Inc. have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. Under the multiyear collaboration, Angelini Pharma will leverage Quiver’s technology platform to gain deeper understanding of a broad set of developmental and epileptic encephalopathies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729017</guid>
      <pubDate>Tue, 24 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729017-angelini-and-quiver-bioscience-partner-in-genetic-epilepsies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-and-DNA2.webp?t=1663611764" type="image/png" medium="image" fileSize="254381">
        <media:title type="plain">Brain and DNA </media:title>
      </media:content>
    </item>
    <item>
      <title>Financing at Gelmedix supports GMX-101 for geographic atrophy</title>
      <description>
        <![CDATA[Gelmedix Inc. has completed a $13 million seed financing to support progression of the company’s lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage geographic atrophy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728920</guid>
      <pubDate>Wed, 18 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728920-financing-at-gelmedix-supports-gmx-101-for-geographic-atrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RD-money.webp?t=1588877677" type="image/png" medium="image" fileSize="578436">
        <media:title type="plain">Dollar sign droplet above test tube</media:title>
      </media:content>
    </item>
    <item>
      <title>Nektar Therapeutics and UCSF explore TNFR2 agonism in MS</title>
      <description>
        <![CDATA[Nektar Therapeutics Inc. has established an academic research collaboration with the University of California, San Francisco (UCSF) to explore the role of tumor necrosis factor receptor 2 (TNFR2) agonism in models of multiple sclerosis (MS) with the aim of supporting progression of NKTR-0165, Nektar’s first-in-class TNFR2 agonist antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728918</guid>
      <pubDate>Wed, 18 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728918-nektar-therapeutics-and-ucsf-explore-tnfr2-agonism-in-ms</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/research-collaboration-deal-handshake-gloves.webp?t=1765812758" type="image/jpeg" medium="image" fileSize="419449">
        <media:title type="plain">Photo of researchers shaking hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Teijin Pharma and Aska partner in gynecological diseases</title>
      <description>
        <![CDATA[Teijin Pharma Ltd. has entered into a joint research agreement with Aska Pharmaceutical Co. Ltd. to jointly develop novel small-molecule drug candidates for gynecological diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728899</guid>
      <pubDate>Tue, 17 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728899-teijin-pharma-and-aska-partner-in-gynecological-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/womens-health-reproduction-ovaries-uterus-cervix.webp?t=1721747295" type="image/jpeg" medium="image" fileSize="118515">
        <media:title type="plain">Illustration of women's reproductive organs</media:title>
      </media:content>
    </item>
    <item>
      <title>Advancell and 48Hour Discovery partner on 212Pb radiotherapeutic</title>
      <description>
        <![CDATA[Advancell Pty Ltd. has entered into a collaboration and exclusive licensing agreement with 48Hour Discovery Inc. to develop a novel peptide-based lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728512</guid>
      <pubDate>Tue, 03 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728512-advancell-and-48hour-discovery-partner-on-212pb-radiotherapeutic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Radiotherapy-of-cancer.webp?t=1666626496" type="image/png" medium="image" fileSize="567967">
        <media:title type="plain">Radiotherapy of cancer </media:title>
      </media:content>
    </item>
    <item>
      <title>Astrazeneca and CSPC collaborate in obesity and type 2 diabetes</title>
      <description>
        <![CDATA[Astrazeneca plc has signed a new strategic collaboration agreement with CSPC Pharmaceutical Group Ltd. to advance the development of next-generation therapies for obesity and type 2 diabetes across eight programs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728438</guid>
      <pubDate>Fri, 30 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728438-astrazeneca-and-cspc-collaborate-in-obesity-and-type-2-diabetes</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-puzzle-pieces.webp?t=1588276668" type="image/png" medium="image" fileSize="174585">
        <media:title type="plain">Connecting puzzle pieces</media:title>
      </media:content>
    </item>
    <item>
      <title>Sinorda Biomedicine and Wuxi Biologics collaborate on SND-006</title>
      <description>
        <![CDATA[Wuxi Biologics Co. Ltd. and Sinorda Biomedicine have established a strategic collaboration for the development and manufacturing of SND-006, a novel bispecific antibody, for the treatment of inflammatory bowel disease and other autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728417</guid>
      <pubDate>Thu, 29 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728417-sinorda-biomedicine-and-wuxi-biologics-collaborate-on-snd-006</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/IBD-inflammatory-bowel-disease-Crohns-Colitis.webp?t=1745258495" type="image/jpeg" medium="image" fileSize="193405">
        <media:title type="plain">Illustration of intestines with inflammation</media:title>
      </media:content>
    </item>
    <item>
      <title>SCN2A Foundation and Unravel Biosciences collaborate</title>
      <description>
        <![CDATA[The SCN2A Foundation has entered into a research collaboration with Unravel Biosciences Inc. to advance preclinical research for SCN2A-related disorders caused by loss-of-function mutations, a subset of SCN2A conditions driven by insufficient functional protein.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728415</guid>
      <pubDate>Thu, 29 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728415-scn2a-foundation-and-unravel-biosciences-collaborate</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-mutation.webp?t=1674229694" type="image/png" medium="image" fileSize="1464740">
        <media:title type="plain">DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Starkage and Gustave Roussy research cellular senescence</title>
      <description>
        <![CDATA[Starkage Therapeutics SAS has established a research collaboration with Gustave Roussy to characterize cellular senescence induced by standard-of-care treatments in a series of digestive cancers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728379</guid>
      <pubDate>Tue, 27 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728379-starkage-and-gustave-roussy-research-cellular-senescence</link>
    </item>
    <item>
      <title>Mair Therapeutics and Radboud collaborate in Parkinson’s</title>
      <description>
        <![CDATA[Mair Therapeutics BV has established a scientific collaboration with Radboud University to accelerate the discovery of small-molecule agonists of TMEM175, a lysosomal ion channel genetically linked to Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728376</guid>
      <pubDate>Tue, 27 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728376-mair-therapeutics-and-radboud-collaborate-in-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neurology-brain-puzzle-alzheimers-parkinsons.webp?t=1745263787" type="image/jpeg" medium="image" fileSize="303211">
        <media:title type="plain">Elderly woman holding illustration of brain with missing puzzle piece</media:title>
      </media:content>
    </item>
    <item>
      <title>Boehringer Ingelheim and Simcere partner on SIM-0709</title>
      <description>
        <![CDATA[Boehringer Ingelheim International GmbH and Simcere Pharmaceutical Group Ltd. have entered into a license and collaboration agreement to develop SIM-0709 for the treatment of inflammatory bowel disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728375</guid>
      <pubDate>Tue, 27 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728375-boehringer-ingelheim-and-simcere-partner-on-sim-0709</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/global-business-trade-deal.webp?t=1588276966" type="image/png" medium="image" fileSize="2119366">
        <media:title type="plain">Handshake with digital globe overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Insilico Medicine and Hygtia partner on ISM-8969</title>
      <description>
        <![CDATA[Insilico Medicine Cayman Topco and Hygtia Therapeutics Co. Ltd. have entered into an exclusive license and co-development collaboration to advance ISM-8969 worldwide. ISM-8969 is an orally available, brain penetrant NLRP3 inhibitor for CNS disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728186</guid>
      <pubDate>Wed, 21 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728186-insilico-medicine-and-hygtia-partner-on-ism-8969</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-as-filament-in-light-bulb.webp?t=1695304772" type="image/jpeg" medium="image" fileSize="168302">
        <media:title type="plain">Brain as light bulb filament</media:title>
      </media:content>
    </item>
  </channel>
</rss>
